เกี่ยวกับตอนนี้
Automated insulin delivery (AID) relies on the accuracy of the sensor behind it—so what happens when “70% time in range” doesn’t mean the same thing across different continuous glucose monitoring (CGM) systems?
Recorded at EASD in Vienna, this special episode of Within Range brings together clinical, research and real-world perspectives to unpack how CGM accuracy, comparator methods (capillary vs venous) and standardisation efforts shape the numbers healthcare professionals rely on every day.
Registered dietitian and diabetes educator John Pemberton uses a powerful “strict vs lenient marker” analogy to explain why identical time in range figures can mask very different glucose exposure—and why pairing CGM metrics with HbA1c remains critical.
Then Insulet’s Medical Affairs team sit down with CGM experts Dr Guido Freckmann and Dr Othmar Moser to discuss new data comparing current-generation sensors (including in exercise settings), the push for unified CGM evaluation standards, implications for hybrid closed loop safety, and what health care professionals should consider when interpreting trials, real-world datasets and choosing AID systems with their patients.
Who you’ll hear from on this episode:
· Kate Neal - Clinical Services Manager at Insulet.
· Irene Hadjiyianni - Director, Medical Affairs Europe at Insulet.
· Séverine Labat – Senior Director of Medical Affairs at Insulet.
· John Pemberton – Registered dietitian and diabetes educator, sharing practical insights from supporting approximately 300 children and young people with type 1 diabetes, and how he translates sensor accuracy data into real-world AID decisions.
· Dr Guido Freckmann – Medical Director, Institute of Diabetes Technology in Germany, outlining a new challenging study procedure for CGM evaluation, key findings on sensor differences, and the drive towards clear accuracy targets.
· Dr Othmar Moser – Exercise physiology and metabolism expert, presenting data on CGM performance during physical activity, and what accuracy means for safety and trust in automated insulin delivery.
Disclaimer
Note: The information in this podcast is accurate to the date of recording as of 09/17/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.
Clinical data referenced in this episode can be found here:
Eichenlaub M et al. Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2025 Feb 4:19322968251315459. doi: 10.1177/19322968251315459. Epub ahead of print. PMID: 39902649; PMCID: PMC11795573.
INS-OHS-11-2025-00087 v1.0
